LONDON – Sixteen of Europe's leading medical research organizations have taken issue with the centerpiece of proposed reforms to the rules for setting up and running multinational clinical trials, saying that rather than streamlining things there is a risk of increasing cost and approval times. (BioWorld International) Read More
